TY - JOUR
T1 - Managing skin toxicities related to panitumumab
AU - Bergman, Hagit
AU - Walton, Tara
AU - Del Bel, Ryan
AU - Seki, Jack T.
AU - Rafii, Ava
AU - Xu, Wei
AU - Koren, Gideon
AU - Shear, Neil
AU - Krzyzanowska, Monika K.
AU - Howell, Doris
AU - Liu, Geoffrey
N1 - Funding Information:
Supported by Cancer Care Ontario and Ontario Patient-Reported Outcomes of Symptoms and Toxicity . Dr Liu is supported by the Alan B. Brown Chair in Molecular Genomics and the Posluns Family Fund . Dr Howell is supported by the Royal Bank of Canada (RBC) Chair in Oncology Nursing Research .
PY - 2014
Y1 - 2014
N2 - Background: Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment. Objective: We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment. Methods: This was a retrospective chart review. Results: Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity. Limitations: Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients. Conclusion: Dermatologic toxicities related to panitumumab are common; however, theway they are reported andmanaged variesamongphysicians.Topreventprogression, toxicitiesmust be assessedandtreatedearly and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies. ( J Am Acad Dermatol 2014;71:754-9.).
AB - Background: Dermatologic toxicities from targeted agents such as panitumumab can interfere with cancer treatment. Objective: We sought to evaluate the rash assessment and management in a consecutive patient cohort who received panitumumab for colorectal cancer treatment. Methods: This was a retrospective chart review. Results: Skin toxicity, consisting of papulopustular rash, was experienced by 32 of 34 patients. The majority (85%) developed the rash by the end of the second infusion cycle. Patients presented with a mild (41%), moderate (38%), and severe (21%) rash, and progressed to an extensive rash without appropriate treatment. A grading system was used for 65% of patients to document severity. Limitations: Small sample size limited power in analysis. Rash severity had to be inferred based on rash description and management in 11 of the patients. Conclusion: Dermatologic toxicities related to panitumumab are common; however, theway they are reported andmanaged variesamongphysicians.Topreventprogression, toxicitiesmust be assessedandtreatedearly and aggressively, according to severity grading. Dermatologists could aid oncologists in choosing the best management strategies. ( J Am Acad Dermatol 2014;71:754-9.).
KW - Common Toxicity Criteria for Adverse Events
KW - Epidermal growth factor receptor inhibitors
KW - Panitumumab
KW - Papulopustular rash
KW - Skin toxicity
UR - https://www.scopus.com/pages/publications/84910131661
U2 - 10.1016/j.jaad.2014.06.011
DO - 10.1016/j.jaad.2014.06.011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 25085331
AN - SCOPUS:84910131661
SN - 0190-9622
VL - 71
SP - 754
EP - 759
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 4
ER -